AIMS: International guidelines are frequently not implemented in the elderly population with heart failure (HF). This study determined the management of octogenarians with HF enrolled in Euro Heart Failure Survey II (EHFS II) (2004-05). METHODS AND RESULTS: We compared the clinical profile, 12 month outcomes, and management modalities between 741 octogenarians (median age 83.7 years) and 2836 younger patients (median age 68.4 years) hospitalized for acute/decompensated HF. Management modalities were also compared with those observed in EHFS I (2000-01). Female gender, new onset HF (de novo), hypertension, atrial fibrillation, co-morbidities, disabilities, and low quality of life were more common in the elderly (all P < 0.001). Mortality rates during hospital stay and during 12 months after discharge were increased in octogenarians (10.7 vs. 5.6% and 28.4 vs. 18.5%, P < 0.001). Underuse and underdosage of medications recommended for HF were observed in the elderly. However, a significant improvement was observed when compared with EHFS I both in the overall HF octogenarian population and in the subgroup with ejection fraction < or =45% for prescription rates of ACE-I/ARBs, beta-blockers, and aldosterone antagonists at discharge (82 vs. 71%; 56 vs. 29%; 54 vs. 18.5%, respectively, all P < 0.01), as well as for recommended combinations and dosage. Prescription rates remained stable for 12 months after discharge in survivors. CONCLUSION: Our study confirms that the contemporary management of very elderly patients with HF remains suboptimal but that the situation is improving.
AIMS: International guidelines are frequently not implemented in the elderly population with heart failure (HF). This study determined the management of octogenarians with HF enrolled in EuroHeart Failure Survey II (EHFS II) (2004-05). METHODS AND RESULTS: We compared the clinical profile, 12 month outcomes, and management modalities between 741 octogenarians (median age 83.7 years) and 2836 younger patients (median age 68.4 years) hospitalized for acute/decompensated HF. Management modalities were also compared with those observed in EHFS I (2000-01). Female gender, new onset HF (de novo), hypertension, atrial fibrillation, co-morbidities, disabilities, and low quality of life were more common in the elderly (all P < 0.001). Mortality rates during hospital stay and during 12 months after discharge were increased in octogenarians (10.7 vs. 5.6% and 28.4 vs. 18.5%, P < 0.001). Underuse and underdosage of medications recommended for HF were observed in the elderly. However, a significant improvement was observed when compared with EHFS I both in the overall HF octogenarian population and in the subgroup with ejection fraction < or =45% for prescription rates of ACE-I/ARBs, beta-blockers, and aldosterone antagonists at discharge (82 vs. 71%; 56 vs. 29%; 54 vs. 18.5%, respectively, all P < 0.01), as well as for recommended combinations and dosage. Prescription rates remained stable for 12 months after discharge in survivors. CONCLUSION: Our study confirms that the contemporary management of very elderly patients with HF remains suboptimal but that the situation is improving.
Authors: K Guha; D Konstantinou; L Mantziari; B N Modi; B Chandrasekaran; Z Khalique; T McDonagh; R Sharma Journal: J Interv Card Electrophysiol Date: 2013-11-29 Impact factor: 1.900
Authors: Willemien J Kruik-Kollöffel; Gerard C M Linssen; H Joost Kruik; Kris L L Movig; Edith M Heintjes; Job van der Palen Journal: Heart Fail Rev Date: 2019-07 Impact factor: 4.214
Authors: Alain Cohen-Solal; Dipak Kotecha; Dirk J van Veldhuisen; Daphne Babalis; Michael Böhm; Andrew J Coats; Michael Roughton; Philip Poole-Wilson; Luigi Tavazzi; Marcus Flather Journal: Eur J Heart Fail Date: 2009-08-01 Impact factor: 15.534